Prothena Corporation plc - Ordinary Shares (PRTA): Price and Financial Metrics
PRTA Stock Summary
- Prothena Corp Public Ltd Co's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 8.49% of US listed stocks.
- PRTA's price/sales ratio is 1,017.73; that's higher than the P/S ratio of 99.21% of US stocks.
- With a year-over-year growth in debt of -22.24%, Prothena Corp Public Ltd Co's debt growth rate surpasses just 15.07% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Prothena Corp Public Ltd Co, a group of peers worth examining would be VTGN, MRKR, KLDO, BCDA, and OTIC.
- PRTA's SEC filings can be seen here. And to visit Prothena Corp Public Ltd Co's official web site, go to www.prothena.com.
PRTA Stock Price Chart Interactive Chart >
PRTA Price/Volume Stats
|Current price||$21.91||52-week high||$27.20|
|Prev. close||$21.71||52-week low||$7.10|
|Day high||$22.66||Avg. volume||461,036|
|50-day MA||$15.74||Dividend yield||N/A|
|200-day MA||$12.64||Market Cap||876.12M|
Prothena Corporation plc - Ordinary Shares (PRTA) Company Bio
Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The company was founded in 2012 and is based in Dublin, Ireland.
PRTA Latest News Stream
|Loading, please wait...|
PRTA Latest Social Stream
View Full PRTA Social Stream
Latest PRTA News From Around the Web
Below are the latest news stories about Prothena Corp Public Ltd Co that investors may wish to consider to help them evaluate PRTA as an investment opportunity.
Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
Robust preclinical data support the benefit of PRX005, a novel anti-tau antibody, for the potential treatment Alzheimer’s diseaseNew pre-specified exploratory subgroup analyses and new digital biomarker data from Part 1 of the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson’s disease will be featured in two separate presentations DUBLIN, Ireland, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced three oral presentations and participation in a live forum at The 15th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2021). Prothen...
Today Prothena Corporation ([[PRTA]] +28.7%) reached what could be its highest intraday gain in more than two years as Jefferies upgraded the stock to buy from neutral expecting a 100% upside to the stock.Citing the ‘positive momentum and pipeline execution’ and rising investor attention, the analyst Michael Yee ups the...
Corvus Pharmaceuticals (NASDAQ: CRVS ) shares are … Full story available on Benzinga.com
Prothena (NASDAQ:PRTA) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.77) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.77), MarketWatch Earnings reports. Prothena had a negative return on equity of 41.97% and a negative net margin of 13,615.75%. PRTA traded up $7.15 during midday trading on Friday, hitting […]
Prothena (PRTA) beats on earnings in the fourth quarter of 2020 and surpasses sales estimates too.
PRTA Price Returns
Continue Researching PRTAWant to do more research on Prothena Corp plc's stock and its price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!